First-line treatment of multiple myeloma in elderly patients: The GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective

Current Drug Targets

Volumn 10, Issue 10, 2009, Pages 906-922

  Musto, Pellegrino ^a,b   D'Auria, Fiorella ^a   Pietrantuono, Giuseppe ^a   Baldini, Luca ^b   Bringhen, Sara ^b   Caravita, Tommaso ^b   Di Raimondo, Francesco ^b   Morabito, Fortunato ^b   Offidani, Massimo ^b   Petrucci, Maria Teresa ^b   Tosi, Patrizia ^b   Gay, Francesca ^b   Cavo, Michele ^b   Boccadoro, Mario ^b   Palumbo, Antonio ^b  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Multiple Myeloma Working Party   (Italy)

Author keywords

Autologous transplantation; Bendamustine; Bortezomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Elderly; Lenalidomide; Myeloma; Reduced intensity allogeneic transplantation; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA2B INTERFERON; BENDAMUSTINE; BETA 2 MICROGLOBULIN; BORTEZOMIB; CARMUSTINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; PLACEBO; PREDNISONE; RECOMBINANT ALPHA2 INTERFERON; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANXIETY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; ELDERLY CARE; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; HEALTH CARE ORGANIZATION; HEALTH STATUS; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; HYPERGLYCEMIA; INFECTION; ITALY; LEUKOPENIA; LIFESPAN; LUNG EMBOLISM; MORBIDITY; MORTALITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NEUTROPENIA; OVERALL SURVIVAL; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PNEUMONIA; PRACTICE GUIDELINE; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; MELPHALAN; MULTIPLE MYELOMA; QUALITY OF LIFE; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 70450209034     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789577936     Document Type: Review

References (114)

1. Phekoo KJ, Schey SA, Richards MA, Bevan DH, Bell S, Gillett D, et al. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004; 127: 299-330 (Pubitemid 39468943)
2. Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol 2007; 20: 637-664
3. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004; 22: 4626-4631 (Pubitemid 41185131)
4. Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J. Myeloma in patients younger than age 50 years presents with more favourable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008; 111: 4039-4047
5. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2526
6. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520
7. Anagnostopoulos A, Gika D, Symeonidis A, Zervas K, Pouli A, Repoussis P, et al. Multiple myeloma in elderly patients: prognostic factors and outcome. Eur J Haematol 2005; 75: 370-375. (Pubitemid 41445075)
8. Palumbo A, Avonto I, Bringhen S, Falcone A, Liberati M, Boccadoro M, et al. Hematologic cancer in the elderly: many patients, much to do. ASCO, American Society of Clinical Oncology Educational Book 2007; 288-295
9. Westin EH, Longo DL. Lymphoma and myeloma in older patients. Semin Oncol 2004; 31: 198-205.
10. Wedding U, Rohrig B, Klippstein A, Pientka L, Hoffken K. Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol 2007; 133: 945-950 (Pubitemid 47561710)
11. Mileshkin L, Prince HM. The adverse prognostic impact of advanced age in multiple myeloma. Leuk Lymphoma 2005; 46: 951-966 (Pubitemid 40975015)
12. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33. (Pubitemid 36033957)
13. Cavallo F, Ambrosini MT, Rus C, Boccadoro M, Palumbo A. The treatment of the elderly multiple myeloma patients. Leuk Lymphoma 2007; 48: 469-480 (Pubitemid 46487753)
14. Bladé J, Rosiñol L. Advances in therapy of multiple myeloma. Curr Opin Oncol 2008; 20: 697-704.
15. Palumbo A, Rajkumar SV. Treatment of newly diagnosed myeloma. Leukemia 2009; 23: 449-456
16. Harousseau JL. Induction therapy in multiple myeloma. Hematology Am Soc Hematol Educ Program 2008; 306-312
17. Moreau P, Hulin C, Facon T. Frontline treatment of multiple myeloma in elderly patients. Blood Rev 2008; 22: 303-309
18. Görner M, Späth-Schwalbe E. Task Force Geriatrische Onkologie of the DGHO, OGHO, DGG and AIO. Modern treatment options for elderly patients with multiple myeloma. Onkologie 2008; 31: 335-342
19. San Miguel JF, Facon T, Cavo M. Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practice. Clin Adv Hematol Oncol 2008; 6 (4 Suppl 10): 1-12.
20. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757
21. He Y, Wheatley K, Clark O, Glasmacher A, Ross H, Djulbegovic B. Early versus deferred treatment for early stage multiple myeloma. Cochrane Database Syst Rev 2003; (1): CD004023.
22. Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356: 2582-2590 (Pubitemid 46961003)
23. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
24. Rajkumar SV, Gertz MA, Lacy MQ, Dispensieri A, Fonseca R, Geyer SM, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-779 (Pubitemid 36519375)
25. Barlogie B, van Rhee F, Shaughnessy JD Jr, Epstein J, Yaccoby S, Pineda-Roman M, et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 2008; 112: 3122-3125
26. Musto P, Falcone A, Sanpaolo G, Bodenizza C, Cascavilla N, Melillo L, et al. Pamidronate reduces skeletal events but does notimprove progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk Lymphoma 2003; 44: 1545-1548 (Pubitemid 36833970)
27. Musto P, Petrucci MT, Bringhen S, Guglielmelli T, Caravita T, Bongarzoni V, et al. GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008; 113: 1588-1595
28. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007; 25: 2464-2472
29. Musto P, D'Auria F. Melphalan: old and new uses of a still master drug for multiple myeloma. Exp Opin Invest Drugs 2007; 25: 4459-4465
30. Facon T, Mary JY, Pegourie B, Attal M, Renaud M, Sadoun A, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006; 107: 1292-1298 (Pubitemid 43242361)
31. Hernandez JM, Garcia-Sanz R, Golvano E, Bladé J, Fernandez-Calvo J, Trujillo J, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004; 127: 159-164 (Pubitemid 39371808)
32. Shustik C, Belch A, Robinson S, Rubin SH, Dolan SP, Kovacs MJ, et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma. Br J Haematol 2007; 136: 203-211 (Pubitemid 46020747)
33. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10: 334-342
34. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan and prednisone as treatment of multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832-3842
35. Kyle RA, Leong T, Li S, Oken MM, Kay NE, Van Ness B, et al. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer 2006; 106: 1958-1966 (Pubitemid 43673211)
36. Ponisch W, Mitrou PS, Merkle K. Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132: 205-212 (Pubitemid 43144255)
37. Garcia-Sanz R, Hernandez JM, Sureda A, Garcia-Laraña J, Prosper F, Alegre A, et al. Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma. Hematol Oncol 2006; 24: 205-211 (Pubitemid 46032894)
38. Palumbo A, Facon T, Sonneveld P, Bladè J, Offidani M, Gay F, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111: 3968-3977
39. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 3419-3423 (Pubitemid 35266292)
40. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
41. Dingli D, Rajkumar SV, Nowakowski GS, Gertz MA, Dispenzieri A, Lacy MQ, et al. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Haematologica 2005; 90: 1650-1654 (Pubitemid 41814989)
42. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436 (Pubitemid 46630462)
43. Rajkumar SV, Rosiñol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008; 26: 2171-2177
44. Ludwig H, Hajek R, Tothova E, Drach J, Adam Z, Labar B, et al. Thalidomide-dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009; 113: 3435-3442
45. Musto P, D'Auria F, Pietrantuono G, Bringhen S, Morabito F, Di Raimondo F, et al. Role of thalidomide in previously untreated patients with multiple myeloma. Expert Rev Anticancer Ther 2008; 8: 1569-1580
46. Hicks LK, Haynes AE, Reece DE, Walker IR, Herst JA, Meyer RM, et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 2008; 34: 442-452
47. Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Nunzi M, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer 2005; 104: 1428-1433 (Pubitemid 41356158)
48. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825-831 (Pubitemid 43363369)
49. Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, et al. Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: updated results of a randomised controlled trial. Blood 2008; 112: 3107-3114
50. Facon T, Mary J, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209-1218 (Pubitemid 47516593)
51. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 Trial. J Clin Oncol 2009 May 18. [Epub ahead of print]
52. Dimopoulos MA, Anagnostopoulos A, Terpos E, Repoussis P, Zomas A, Katodritou E, et al. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 2006; 91: 252-254 (Pubitemid 43304148)
53. Mateos MV, San Miguel JF. Bortezomib in multiple myeloma. Best Pract Res Clin Haematol 2007; 20(4): 701-715
54. Mateos MV, Hernandez JM, Hernandez MT, Gutiérrez NC, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006; 108: 2165-2172 (Pubitemid 44497496)
55. Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008; 93: 560-565
56. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 964-966
57. Falco P, Cavallo F, Larocca A, Liberati AM, Musto P, Boccadoro M, et al. Lenalidomide and its role in the management of multiple myeloma. Expert Rev Anticancer Ther 2008; 8: 865-874
58. Dimopoulos MA, Kastritis E, Rajkumar SV. Treatment of plasma cell dyscrasias with lenalidomide. Leukemia 2008; 22: 1343-1353
59. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA - Italian multiple myeloma network. J Clin Oncol 2007; 25: 4459-4465 (Pubitemid 350063804)
60. Palumbo A, Falco P, Falcone A, Benevolo G, Canepa L, Gay F, et al. Melphalan, Prednisone, and Lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. Clin Lymphoma Myeloma 2009; 9: 145-150
61. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone for newly diagnosed myeloma. Blood 2005; 106: 4050-4053 (Pubitemid 41775908)
62. Lacy M, Gertz M, Dispenzieri A, Hayman SP, Geyer S, Kabat B, et al. Long term results of response to therapy, time to progression and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007; 82(10): 1179-1184 (Pubitemid 47502875)
63. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood. 2009 Mar 26. [Epub ahead of print]
64. Niesvizky R, Jayabalan DS, Christos PJ, Furst JR, Naib T, Ely S, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naïve symptomatic multiple myeloma. Blood 2008; 111: 1101-1109 (Pubitemid 351213388)
65. Bensinger WI. Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia 2009; 23: 442-448
66. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533-539 (Pubitemid 30137869)
67. Jantunen E. Autologous stem cell transplantation beyond 60 years of age. Bone Marrow Transplant 2006; 38: 715-720. (Pubitemid 44756440)
68. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Leung N, et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2007; 39: 605-611 (Pubitemid 46729052)
69. Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600-607 (Pubitemid 32953638)
70. Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 2007; 39: 279-283 (Pubitemid 46322634)
71. Jantunen E, Kuittinen T, Penttila K, Lehtonen P, Mahlamaki E, Nousiainen T. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006; 37: 917-922 (Pubitemid 43792551)
72. Bishton M, Gilyead M, Das Gupta E, Williams C, Russell NH, Byrne JL. High dose melphalan or intermediate dose melphalan can be well tolerated and result in good response rates in selected elderly patients with myeloma. Leuk Res 2007; 31: 1071-1076 (Pubitemid 46873732)
73. Reece DE, Bredeson C, Perez WS. Autologous stem cell transplantation in multiple myeloma patients 〈60 vs 〉/=60years of age. Bone Marrow Transplant 2003; 32: 1135-1143 (Pubitemid 38081225)
74. Kumar SK, Dingli D, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. Am J Hematol 2008; 83: 614-617
75. Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, et al. Dose intensive melphalan with stem-cell support is superior to standard treatment in elderly myeloma patients. Blood 1999; 94: 1248-1253 (Pubitemid 29380405)
76. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104: 3052-3057 (Pubitemid 39507119)
77. Palumbo A, Bringhen S, Bertola A, Cavallo F, Falco P, Massaia M, et al. Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2). Leukemia 2004; 18: 133-138 (Pubitemid 38159449)
78. Kumar A, Kharfan-Dabaja MA, Glasmacher A, Djulbegovic B. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009; 101: 100-106
79. Gahrton G, Björkstrand B. Allogeneic transplantation in multiple myeloma. Haematologica 2008; 93: 1295-1300
80. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367-373 (Pubitemid 35203509)
81. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755-760. (Pubitemid 34832597)
82. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110-1120 (Pubitemid 46425595)
83. Rosiñol L, Pérez-Simón JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591-3593
84. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474-3480
85. Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009; 113: 3383-3391
86. Moreau P, Garban F, Attal M, Michallet M, Marit G, Hulin C, et al. Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing non-myeloablative allotransplantation with autologous transplantation in high-risk de novo mult myeloma. Blood 2008; 112: 3914-3915
87. Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, et al. Maintenance therapy with alternate day prednisone improves survival in multiple myeloma patients. Blood 2002; 99: 3163-3168 (Pubitemid 34525294)
88. The Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113: 1020-1034
89. Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomized trials among 3948 patients. Ann Oncol 2000; 11: 1427-1436
90. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, et al. A randomized trial of maintenance therapy with intron A following high dose melphalan and ABMT in myeloma. Br J Haematol 1998; 102: 195-202.
91. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of Phase III US Intergroup trial S9321. J Clin Oncol 2006; 24: 929-936 (Pubitemid 46638847)
92. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic stem cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030 (Pubitemid 43357806)
93. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 2006; 15: 3289-3294
94. Abdelkefi A, Ladeb S, Torjman L, Othman TB, Lakhal A, Romdhane NB, et al. Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 2008; 111: 1805-1810
95. Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009; 27: 1788-1793
96. Wedding U, Röhrig B, Klippstein A, Pientka L, Höffken K. Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol 2007; 133: 945-950
97. Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20: 494-502.
98. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007; 25: 1824-1831 (Pubitemid 46860271)
99. Patriarca F, Petrucci MT, Bringhen S, Baldini L, Caravita T, Corradini P, et al. Considerations in the treatment of multiple myeloma: A consensus statement from Italian experts. Eur J Haematol 2009; 82: 93-105.
100. Lonial S, Cavenagh J. Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. Br J Haematol. 2009 Mar 14. [Epub ahead of print]
101. Facon T, San Miguel J, Mateos MV, Hulin C. Frontline treatment in elderly patients with multiple myeloma. Semin Hematol 2009; 46: 133-142
102. Kumar SK, Hayman SR, Kyle RA. Autologous stem cell transplantation in the elderly including pre- and post-treatment options. Bone Marrow Transplant 2007; 40: 1115-1121
103. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035-2042
104. Stewart AK. Reduced intensity allogeneic transplantation for myeloma: reality bites. Blood 2009; 113: 3135-3136
105. Harousseau JL. Maintenance treatment in multiple myeloma. Ann Oncol 2008; 19(4): iv54-5.
106. Moreau P, Coiteux V, Hulin C, Leleu X, van de Velde H, Acharya M, et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica 2008; 93: 1908-1911
107. Dingli D, Pacheco JM, Nowakowski GS, Kumar SK, Dispenzieri A, Hayman SR, et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007; 25: 4933-4937 (Pubitemid 350220425)
108. Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, et al. Influence of pre- and post- transplantation responses on outcome of patients with multiple myeloma: sequential improvements of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26: 5775-5782
109. Kyle RA, Leong T, Li S, Oken MM, Kay NE, Van Ness B, et al. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer 2006; 106: 1958-1966
110. Pineda-Roman M, Bolejack V, Arzoumanian V, Anaissie E, van Rhee F, Zangari M, et al. Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol 2007; 136: 393-399
111. Haessler J, Shaughnessy JD Jr, Zhan F, Crowley J, Epstein J, van Rhee F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13: 7073-7079
112. Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. J Clin Oncol 2008; 26: 4798-4805
113. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008; 9: 1157-1165
114. Mitsiades CS, Hideshima T, Chauhan D, McMillin DW, Klippel S, Laubach JP, et al. Emerging tretments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol 2009; 46: 166-175